Physician profile
George Charnock
NPI 1235292533
$61,023.54
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $14K · 2021: $1,781 · 2022: $25K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $57,657.54 | 2019-2022 | |
| Zealand Pharma US, INC. | $1,403.97 | 2020-2022 | |
| Abbvie INC. | $366.78 | 2019-2022 | |
| Dexcom, INC. | $310.08 | 2020-2022 | |
| Lifescan, INC. | $266.90 | 2020-2022 | |
| Mannkind Corporation | $262.17 | 2019-2022 | |
| Abbott Laboratories | $256.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.20 | 2019-2022 | |
| Corcept Therapeutics | $77.97 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $71.31 | 2019-2020 | |
| Valeritas, INC. | $64.08 | 2019 | |
| Medtronic Minimed, INC. | $42.21 | 2019 | |
| Companion Medical, INC. | $36.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.59 | 2019 | |
| Amgen INC. | $22.01 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Charnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.